Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2025-11-06 00:00:00 ET · period of report 2025-11-05 · accession 0002020969-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-06 | 2025-11-05 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +84.9K | 753.1K | +13% | $0 |
| D | 2025-11-06 | 2025-11-05 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +169.9K | 169.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-11-05 | A | A | 84,925 | $0.00 | 753,122 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-11-05 | A | A | 169,851 | $0.00 | 169,851 | D | $4.96 · — to 2035-11-05 | 169,851 Class A Common Stock | (F2) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |